Caplin Point Laboratories Ltd (CAPLIPOINT)
₹2,770.10
Mkt cap
₹21,390 Cr
P/E ratio
32.20
P/B
6.25
Div yield
0.28%
ROE
20.90%
ROCE
24.20%
EPS (TTM)
₹86.03
Book value
₹443
52W range
1,505–2,845
Sector
Healthcare
Price history
Previous close
Caplin Point Laboratories Ltd is engaged in the manufacturing and sourcing of APIs, finished formulations, R&D, clinical research with presence in Latin America, Africa, USA and other nations. [1]
NSE CAPLIPOINTBSE 524742
Health check
Constructive
ValuationFair
ProfitabilityStrong
GrowthHigh
TechnicalsBullish
52-week range
−2.63% from high₹2,770
₹1,505+84.08% from low₹2,845
Current
₹2,770.10
Prev close
₹2,821.00
Day
−1.80%
Price performance
1D
−1.80%
1W
+2.17%
1M
+5.58%
3M
+19.95%
6M
+67.55%
1Y
+30.21%
YTD
+49.83%
Financials
Revenue, profit & margin
P/E ratio
32.2×
CAPLIPOINT is 8% below the sector median of 35.1×
CAPLIPOINT32.2×
Sector median35.1×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 395 | 410 | 436 | 453 | 459 | 483 | 493 | 502 | 510 | 534 | 543 | 600 | 610 | |
| Expenses | 269 | 273 | 293 | 308 | 307 | 318 | 331 | 334 | 332 | 345 | 353 | 396 | 397 | |
| Operating Profit | 127 | 137 | 142 | 145 | 152 | 165 | 162 | 168 | 178 | 189 | 190 | 204 | 213 | |
| OPM % | 32% | 34% | 33% | 32% | 33% | 34% | 33% | 33% | 35% | 35% | 35% | 34% | 35% | |
| Other Income | 12 | 21 | 17 | 17 | 19 | 21 | 31 | 26 | 23 | 30 | 34 | 28 | 34 | |
| Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | |
| Depreciation | 11 | 12 | 14 | 16 | 16 | 17 | 16 | 17 | 16 | 18 | 19 | 19 | 22 | |
| Profit before tax | 127 | 146 | 145 | 146 | 154 | 168 | 177 | 177 | 184 | 201 | 204 | 213 | 225 | |
| Tax % | 18% | 20% | 18% | 17% | 19% | 22% | 21% | 18% | 18% | 20% | 19% | 19% | 20% | |
| Net Profit | 104 | 116 | 120 | 121 | 125 | 131 | 140 | 145 | 151 | 160 | 166 | 173 | 179 | |
| EPS in Rs | 13.62 | 15.13 | 15.43 | 16.01 | 16.31 | 17.21 | 18.28 | 18.76 | 20.10 | 20.32 | 21.56 | 22.38 | 23.27 | |
| Raw PDF |
Earnings
Results dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −0.13% · closed higher next day 19 of last 40
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 10 Nov '23 | 9 Feb '24 | 17 May '24 | 7 Aug '24◦ | 8 Nov '24 | 7 Feb '25◦ | 15 May '25◦ | 7 Aug '25◦ | 5 Nov '25◦ | 5 Feb '26 | 14 May '26 | 12 Aug '26 |
| Earnings day | +8.36% | −0.77% | −1.65% | −6.27% | −5.18% | −4.38% | +0.47% | +2.56% | +0.46% | −0.29% | +9.88% | −5.98% |
| +1 day | +14.06% | +2.88% | −3.58% | −5.07% | −5.16% | −8.15% | +8.02% | +2.40% | −3.14% | −4.39% | +8.52% | −4.94% |
| +5 days | +14.75% | +9.20% | −4.43% | +0.30% | −6.27% | −10.38% | +9.61% | +4.54% | −2.95% | −9.04% | +10.00% | −2.23% |
| +15 days | +12.97% | +6.05% | +0.13% | +20.51% | +8.99% | −18.37% | +4.63% | +3.36% | −4.34% | −9.47% | +10.39% | +3.46% |
| +30 days | +25.81% | −12.76% | +6.49% | +22.70% | +12.98% | −10.22% | +4.17% | +9.49% | −4.39% | −15.99% | +38.88% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
Last 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Interim Dividend - Rs 4 Per Share | 4.00 | 29 May '26 | 30 May '26 |
Shareholding
as of Jun 202670.57%Promoter
Promoters70.57%
FIIs5.76%0.39
DIIs2.49%0.35
Public21.19%0.05
Ownership trend
Peers
8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| SUNPHARMA | ₹1,895.00 | 35.99 | 4,54,674 | 0.84% | 2,901 | +5.95% | 15,300 | +10.46% | 20.53% |
| DIVISLAB | ₹9,315.00 | 83.00 | 2,47,284 | 0.32% | 902 | +65.50% | 3,080 | +27.80% | 21.97% |
| TORNTPHARM | ₹4,914.00 | 83.77 | 1,86,913 | 0.77% | 566 | +5.79% | 4,921 | +54.85% | 15.19% |
| ZYDUSLIFE | ₹1,156.90 | 23.70 | 1,15,401 | 0.09% | 990 | −35.09% | 8,017 | +21.96% | 21.14% |
| CIPLA | ₹1,395.00 | 31.49 | 1,12,696 | 0.93% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| LAURUSLABS | ₹1,876.70 | 92.74 | 1,01,400 | 0.11% | 362 | +125.49% | 2,026 | +29.10% | 17.76% |
| LUPIN | ₹2,105.00 | 16.17 | 96,254 | 0.86% | 1,417 | +16.08% | 8,277 | +32.04% | 29.93% |
| CAPLIPOINT | ₹2,814.00 | 32.15 | 21,390 | 0.28% | 179 | +15.78% | 610 | +19.63% | 24.24% |
| Median: 159 Co. | ₹423.00 | 35.07 | 2,282 | 0.08% | 13 | +29.60% | 162 | +18.62% | 15.04% |
Filings
Annual reports15
Annual Report 2026bseAnnual Report 2025bseAnnual Report 2024bseAnnual Report 2023bseAnnual Report 2022bseAnnual Report 2021bseAnnual Report 2020bseAnnual Report 2019bseAnnual Report 2018bseAnnual Report 2017bseAnnual Report 2016bseAnnual Report 2015bseAnnual Report 2014bseAnnual Report 2013bseAnnual Report 2012bse
Concall transcripts52
TranscriptAug 2026PPTAug 2026RECAug 2026TranscriptMay 2026PPTMay 2026RECMay 2026TranscriptFeb 2026PPTFeb 2026RECFeb 2026TranscriptNov 2025PPTNov 2025RECNov 2025TranscriptAug 2025PPTAug 2025RECAug 2025TranscriptMay 2025PPTMay 2025RECMay 2025TranscriptFeb 2025PPTFeb 2025RECFeb 2025TranscriptNov 2024PPTNov 2024RECNov 2024
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 4 Sep - Newspaper Publication for Notice of 35th AGM and E-Voting InformationLetter To Shareholders 4 Sep - Caplin Point sent AGM notice and FY26 annual report web link; AGM on September 25, 2026.Business Responsibility and Sustainability Reporting (BRSR) 3 Sep - Caplin Point filed BRSR for FY 2025-26, outlining ESG targets, compliance, workforce and operations.Notice Of The 35Th Annual General Meeting 3 SepReg. 34 (1) Annual Report. 3 Sep